Oncología Hepática
Charité
Berlín, AlemaniaPublications en collaboration avec des chercheurs de Charité (23)
2023
-
Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma (Frontiers in Pharmacology, (2023), 14, (1124214), 10.3389/fphar.2023.1124214)
Frontiers in Pharmacology
-
Non-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression
European Radiology, Vol. 33, Núm. 1, pp. 493-500
-
Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients
Journal of Cachexia, Sarcopenia and Muscle, Vol. 14, Núm. 5, pp. 2301-2309
-
Results from the european survey on preoperative management and optimization protocols for PeriHilar cholangiocarcinoma
HPB, Vol. 25, Núm. 11, pp. 1302-1322
-
Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
Frontiers in Pharmacology, Vol. 14
2022
-
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, Núm. 13, pp. 4716-4726
-
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial
Journal of Cancer Research and Clinical Oncology, Vol. 148, Núm. 2, pp. 475-485
-
Correlation of liver enhancement in gadoxetic acid–enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial
European Radiology, Vol. 32, Núm. 2, pp. 1320-1329
-
Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib
Cancer Imaging, Vol. 22, Núm. 1
-
Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Tria
Clinical Cancer Research, Vol. 28, Núm. 17, pp. 3890-3901
-
Extrahepatic Disease in Hepatocellular Carcinoma: Do We Always Need Whole-Body CT or Is Liver MRI Sufficient? A Subanalysis of the SORAMIC Trial
Biomedicines, Vol. 10, Núm. 5
-
Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only—A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort
Current Oncology, Vol. 29, Núm. 2, pp. 565-577
-
Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma
British Journal of Cancer, Vol. 126, Núm. 2, pp. 211-218
-
Utility of the Iwate difficulty scoring system for laparoscopic right posterior sectionectomy: do surgical outcomes differ for tumors in segments VI and VII?
Surgical Endoscopy, Vol. 36, Núm. 12, pp. 9204-9214
2021
-
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
JHEP Reports, Vol. 3, Núm. 3
-
Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma
Journal of Hepatology, Vol. 75, Núm. 6, pp. 1387-1396
-
Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization
EJNMMI Research, Vol. 11, Núm. 1
2020
2019
-
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
Journal of Hepatology, Vol. 71, Núm. 6, pp. 1164-1174
-
Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial
British Journal of Surgery, Vol. 106, Núm. 13, pp. 1837-1846